Covering the operations of the oil and gas industry
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
Sections
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
LNG
Energy Transition
Industry Statistics
Members Only
Special
Webcasts
White Papers
Podcast
Magazine
Surveys
Research
Events
Submit an Article
Iran war
Contact
About Us
Subscribe
Newsletters
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Affiliated Brands
OFFSHORE
ENERGYTECH
MICROGRID KNOWLEDGE
OGJ RESEARCH
Follow us on
http://www.facebook.com/ogjonline
https://www.linkedin.com/company/oil-&-gas-journal
http://twitter.com/ogjonline
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exicure, Inc. - Common Stock
(NQ:
XCUR
)
2.800
-0.380 (-11.95%)
Streaming Delayed Price
Updated: 9:41 AM EDT, May 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exicure, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
October 22, 2025
From
Halper Sadeh LLC
Via
Business Wire
Exicure, Inc. Reports Second Quarter 2025 Financial Results
August 08, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
August 04, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
August 01, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Reports First Quarter 2025 Financial Results
June 27, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
May 28, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
May 05, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
April 14, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
April 11, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Reports Full Year 2024 Financial Results
March 18, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
March 13, 2025
From
Exicure, Inc.
Via
Business Wire
CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
January 23, 2025
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
December 26, 2024
From
Exicure, Inc.
Via
Business Wire
CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
December 21, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
November 14, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
September 18, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
September 09, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
August 26, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
August 19, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
August 15, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
August 08, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
August 01, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Reports First Quarter 2024 Financial Results
June 17, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Reports Full Year 2023 Financial Results
June 06, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
May 23, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Reports Third Quarter 2023 Financial Results
May 16, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
April 22, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
February 05, 2024
From
Exicure, Inc.
Via
Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
November 28, 2023
From
Exicure, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
